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Despite its nearly universal use in clinical practice,
protamine induces adverse reactions ranging from mild
hypotension to idiosyncratic fatal cardiac arrest [14].
The toxicity of protamine is mediated through two
pathways: nonimmunologic pathway, and immuno
globulinmediated pathway. The mechanisms of prota
mineinduced adverse responses via the nonimmuno
logic pathway are attributed to the “crosslinking”
ability of protamine due to its polycationic and poly
meric nature. For instance, complement activation,
which is one of the major events via this nonimmuno
logic pathway, is primarily due to the crosslinking of
heparin by protamine to form antigen–antibody like
large network structures [5]. Anaphylactoid type of
reactions produced via this mechanism, which are
manifested by complement activation, thromboxane
generation, and histamine release, are more common.
However, they can normally be aborted with slow
administration of protamine and thus are less danger
ous. On the contrary, anaphylactic types of responses
produced via immunoglobulinmediated pathway are
unpredictable, not preventable, and always life threat
ening [3, 4].
It is well known that heparin neutralization by prot
amine results from the competitive binding of protamine
with antithrombin III (ATIII) to heparin [6]. Because the
binding between protamine and heparin is electrostatic
and heparin binds ATIII via a small pentasaccharide
sequence [7], it is very likely that only a certain domain
on protamine which encompasses an essential sequence
for favorable electrostatic interaction may fully maintain
heparin neutralization function. Since small peptides
with low molecular weight are usually associated with
diminished or devoid immunogenicity [8], our hypothesis
is that some low molecular weight protamine fragments
derived from protamine may retain antiheparin activity
but be devoid of immunogenicity and “crosslinking”
ability of the native protamine.
In this study, a protamine fragment, which fully
maintains the heparin neutralization function of the par
ent protamine but with much less toxicity, was obtained
by enzymatic digestion of protamine. Heparin neutraliza
tion activity and toxicity of this protamine fraction were
examined both in vitro and in vivo.
MATERIALS AND METHODS
Materials. Protamine sulfate (clupeine from her
ring), thermolysin (EC 3.4.24.4), Freund’s adjuvant, and
goatantimouse IgGalkaline phosphatase were pur
chased from Sigma (USA). Porcine intestine heparin
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Abstract—A new thirteen amino acid peptide, named low molecular weight protamine (LMWP), was obtained through the
enzymatic digestion of native protamine. Both in vitro and in vivo results showed that LMWP fully maintained the heparin
neutralization function of protamine but had much lower immunogenicity and antigenicity. Unlike protamine, neither
LMWP nor LMWP/heparin complexes caused significant blood platelet aggregation in rats. These results suggest that LMWP
can be used as a substitute for protamine for developing a new generation of nontoxic heparin antagonists.
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(169 IU/mg; average molecular weight of 13 kD),
antithrombin III (ATIII), factor Xa, and chromogenic
substrate S2238 were obtained from Pharmacia Hepar
Inc. (USA). Actin cephaloplastin was obtained from Dade
(USA). Fresh frozen human plasma in citrate was
obtained from the American Red Cross in Detroit (USA).
Rats (Sprague–Dawley, 270 ± 23 g) and mice (ICR strain,
67 weekold) were supplied by Harlan Dawley Co (USA).
Preparation of LMWP. Thermolysin and protamine
were mixed in a 1 : 100 ratio in PBS solution containing
20 mM CaCl2. The reaction mixture was incubated for
30 min at room temperature, followed by the addition of
EDTA (50 mM) to quench the protease activity. Low
molecular weight protamine mixture was fractionated on
a heparin affinity column (HiTrap) attached to HPLC by
using a linear NaCl gradient prepared by mixing solutions
of PBS and 2 M NaCl. A total of five peptide fractions
were observed. A pure peptide fragment (termed as
LMWP), which accounts for most of the heparin neutral
ization ability of low molecular weight protamine mix
ture, was obtained and its sequence (VSRRRRRRGGR
RRR) was confirmed by mass spectrum and amino acid
composition analysis.
Determination of heparin neutralization ability of
LMWP in vitro. Heparin neutralization ability of LMWP
was measured in human plasma using the HEPTest® clot
ting assay. In brief, 15 µl of protamine or LMWP solution
(20200 µg/ml) was mixed with 100 µl of heparinized
human plasma (1 U heparin/ml). A mixture of 15 µl of
saline with 100 µl of heparinized human plasma (1 U
heparin/ml) was taken as control. To the mixture, 100 µl
of ATIII was added. After 2 min of incubation, 100 µl of
RECALMIX® (preheated to 37°C) was added, and the
clotting time was measured immediately using a fibrome
ter (Fibrosystem; Becton Dickinson Company, USA).
Determination of heparin neutralization ability of
LMWP in vivo. Female Sprague–Dawley rats (mean
weight 270 ± 23 g) were anaesthetized (50 mg/kg sodium
pentobarbital) and a single jugular vein cannula was
inserted into the right jugular vein. Blood (0.5 ml) was
drawn as a control at 5 min after the injection of 0.4 ml
saline. Heparin (25 U in 0.2 ml saline) was dosed intra
venously and blood samples (0.4 ml) were drawn at 5 min
after heparin injection. Right after that, 0.2 ml protamine
(100 µg/100 g body weight) or LMWP (100250 µg/100 g
body weight) was injected intravenously at a period of
2 min. Blood (0.5 ml) was drawn at 5 min after protamine
injection. Heparin activities in these rat plasmas were
determined by activated partial thromboplastin time
(APTT) test using a fibrometer (Fibrosystem; Becton
Dickinson Company).
Immunogenicity assay of LMWP in mice. The
immunogenicity of protamine and LMWP was examined
in mice. The production of polyclonal antibodies was per
formed according to the method of Cooper and Paterson
[9]. Twentysix ICR mice (67 weekold), 12 for prota
mine and 14 for LMWP, were included in this study. Each
mouse was immunized with 50 µg of protamine or LMWP
in complete Freund’s adjuvant (CFA). The first booster
was given at the fourth week after primary immunization
with 5 µg of protamine (or LMWP) in incomplete
Freund’s adjuvant (IFA). Animals were bled at 2week
intervals. Blood was collected, allowed to clot, and cen
trifuged to collect serum.
Determination of LMWPmediated platelet count
drop. Female Sprague–Dawley rats (mean weight 270 ±
23 g) were anaesthetized (50 mg/kg sodium pentobarbi
tal) and a single jugular vein cannula was inserted into the
right jugular vein. Blood specimens (0.09 ml) were
obtained prior to heparin (10 IU/100 g body weight)
administration, and 5 and 10 min after administration of
protamine (100 µg/100 g body weight) or LMWP
(250 µg/100 g body weight). Platelet count was deter
mined using phase contrast microscopy.
Detection of antiprotamine and antiLMWP anti
bodies by ELISA. High binding 96well ELISA plates
were first coated with 100 µl of equivalent concentra
tion of protamine or LMWP (100 µg/ml) in PBS/Tween
20 (pH 7.5) and allowed to incubate overnight at 4°C.
The unbound protamine or LMWP was removed by
draining the plate and washing 4 times with PBS/Tween
20. The remaining binding sites in the wells were
blocked by incubating the plates with 120 µl/well
PBS/Tween 20 containing 1.0% human serum albumin
for 1 h at 37°C. Antiprotamine and antiLMWP anti
bodies in diluted serum of immunized mice were
detected by the routine ELISA method using goat anti
mouse IgGalkaline phosphatase as the detection anti
body. In competitive ELISA, diluted serum was
replaced with a fixed dilution of serum (100 times) con
taining increasing concentrations (1 to 1000 µg/ml) of
free protamine or LMWP.
RESULTS
A total of eight peptide fractions were obtained after
passing of enzyme digested protamine mixture through a
heparin column (Fig. 1a). Since protamine neutralization
of heparin results from its stronger heparin affinity than
that of ATIII [7], small protamine fractions with weaker
heparin binding strength is predicted to be unable to neu
tralize anticoagulant activity of heparin. In agreement
with this assumption, small protamine fragments with low
heparin affinity (peaks 17, eluted before 0.80 M NaCl
concentration) showed hardly any heparin neutralization
function (data not shown). Only peak number eight
showed high heparin binding strength (eluted at about
0.95 M NaCl concentration) and accounted for most of
the heparin neutralization ability of the enzymedigested
protamine mixture (table). The mass spectrum and amino
acid composition analysis (Fig. 1b) showed that this peak
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containing a single peptide with the sequence of VSR
RRRRRGGRRRR was from the Cterminal of prota
mine and was termed low molecular weight protamine
(LMWP). Antiheparin assay results from both in vitro
and in vivo experiments showed that although the dose
required for complete heparin neutralization was about
two times higher than that of protamine, this peptide fully
maintained the heparin neutralization function of prota
mine (table).
It is known that protaminemediated toxicities are
mainly through an immunoglobulinmediated pathway
because of the production of antiprotamine antibodies
[3, 4]. Since a small peptide with 20 amino acids or less is
usually associated with low immunogenicity, we further
compared the immunogenicity of protamine and LMWP
by monitoring antiprotamine or antiLMWP antibody
production in protamine or LMWPimmunized mice. As
shown in Fig. 2, antibody titers in pooled sera from prot
amineimmunized mice were much higher than those
from LMWPimmunized mice over the entire experi
mental duration (8 weeks). The greatest difference in
antibody production between these two groups was
observed six weeks after the primary immunization, and
Fig. 1. Characterization of fractions from enzymatic digestion
of protamine: a) elution profile of low molecular weight prota
mine fraction; b) massspectrometry and amino acid composi




















Fig. 2. Time course of antibody induction by protamine (1, n =
12) and LMWP (2, n = 14) in mice. Mice received protamine
(50 µg) or LMWP (50 µg) in primary inoculation, and then were
boosted with protamine (10 µg) or LMWP (10 µg) at 4 weeks
after primary immunization. Blood samples were collected every
2 weeks after immunization and antibodies were detected on













Fig. 3. Crossreactivity assay of antiprotamine and anti
LMWP antibodies (dark and light columns, respectively) by
ELISA. The crossreactivity of antiprotamine (1) and anti
LMWP antibodies (2) to LMWP and protamine was detected
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the antibody level in LMWPimmunized mice was three
times lower than that in protamineimmunized mice
(Fig. 2). The crossreactivity of antiprotamine and anti
LMWP to LMWP and protamine was also examined.
Although antiLMWP showed a slightly higher reactivity
to protamine than LMWP, antiprotamine exhibited
much lower crossreactivity to LMWP (Fig. 3).
Protaminemediated adverse responses via the non
immunologic pathway are attributed to the “crosslink
ing” ability of protamine due to its polycationic and poly
meric nature. Either protamine or its complex with
heparin can bind to molecules on the cell membrane and
thus affect cell function [5]. For example, the binding of
protamine or protamine/heparin complexes to platelets
has proved to cause platelet aggregation and induce
thrombocytopenia [10]. To examine if LMWP would
cause less crosslinking reactions as compared to its par
ent protamine, the effect of LMWP on platelet aggrega
tion and thrombocytopenia induction in mice was further
tested by intravenous injection of LMWP in the presence
or absence of heparin. As shown in Fig. 4a, protamine
itself could cause a significant platelet count drop (~25%)
during the period of 515 min after injection, but LMWP
had hardly showed any such aggregation induction func
tion during the same period. In agreement with this
result, LMWP only induced about 10% of platelet count
drop when it was used for heparin neutralization, but
there was no statistical difference between LMWP and the
control group (Fig. 4b). On the contrary, protamine neu
tralization of heparin caused more than 30% of platelet
count drop under the same experimental conditions.
DISCUSSION
In spite of its Food and Drug Administration
approval, adverse reactions of protamine sulfate range from
mild hypotension to idiosyncratic fatal cardiac arrest
because of its immunogenicity and “crosslinking” ability.
In fact, aside from its wellknown use in heparin neutral
ization, protamine is used widely in insulin formulations to
produce longacting insulin (neutral protamine Hagedorn
(NPH) and protamine zinc insulin (PZI)) allowing
insulindependent diabetic patients to achieve euglycemia
with less frequent insulin injections. This previous expo
sure to protamine renders diabetic patients highly suscep








13.8 ± 1.7 (28) 
13.1 ± 2.4 (700) 
protamine
15.2 ± 2.3 (13)
11.8 ± 1.5 (300) 
Neutralization of the anticoagulant activity of heparin by
protamine and LMWP 
Neutralization
Data listed in the table are clotting time (seconds). Data in
brackets are the amount (µg) of protamine or LMWP required
for the complete neutralization of heparin (1 IU/ml in vitro and
25 IU/rat in vivo). Other experimental conditions are as




Fig. 4. a) Comparison of platelet count drops in the blood of rats after intravenous injection of protamine (100 µg/100 g body weight) (1)
and LMWP (250 µg/100 g body weight) (2). Five, four, and two rats were used in protamine (1), LMWP (2), and control (saline) (3) groups,
respectively. Data represent the average of these experiments; * p < 0.05. b) Comparison of protamine (100 µg/100 g body weight) (1) and
LMWP (250 µg/100 g body weight) (2) induced platelet count drops during its neutralization of heparin (10 IU/100 g body weight) in rats.
Blood platelet numbers were measured at 5 min (P5) and 10 min (P10) after protamine or LMWP injection following the heparin injec
tion. Five rats were used for both protamine and LMWP group. Blood platelet levels before heparin injection (H0) were taken as controls
(100%); * p < 0.01 (in comparison with LMWP group); ** p < 0.01 (in comparison with saline group (3)). 
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that 30% of NPHtreated diabetics had IgG antiprota
mine antibodies, and the risk of a hemodynamically signif
icant protamine reaction at the time of cardiac surgery in
insulindependent diabetics was approximately ten times
higher than that in nondiabetic controls [11]. For this rea
son, protamine toxicity has drawn considerable attention
recently and various protaminelike peptides obtained by
either chemical or recombinant synthesis methods have
been tested as substitutes to protamine for their heparin
anticoagulant neutralization activity [1215]. However,
except for the expensive platelet factor 4 (1 mg/US $2800),
none of these peptides have proved to be safe for clinical
use regardless of their heparin neutralization abilities.
Low molecular weight protamine (LMWP) that we
obtained here fully maintains the heparin neutralization
function of its parent protamine (table); it is less
immunogenic than the parent protamine (Fig. 2); it lacks
crossreactivity to antiprotamine antibodies (Fig. 3) and
had hardly any effect on platelet aggregation (Fig. 4).
Therefore, compared to protamine, LMWP possesses
much less toxicity and is highly likely to become a new
nontoxic heparin antagonist. Since antiprotamine anti
bodies exhibits very low crossreactivity to LMWP, the
use of LMWP as a substitute for protamine in heparin
reversal will enable a large population of diabetic patients
which already have antiprotamine antibodies in their
bodies to avoid the risks of immunoglobulinmediated,
fatal protamine responses. In fact, LMWP has also proved
to be an ideal substitute for protamine in its formulation
with insulin and in DNA condensation (data to be pub
lished). Therefore, in addition to heparin neutralization,
less toxic LMWP also possesses great potential for its
applications in other pharmaceutical products such as
insulin formulation and gene therapy.
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